Why We Are Bullish On Bristol-Myers Squibb
We recently updated the Trefis price estimate for Bristol-Myers Squibb to $75 per share. This update was based on a detailed review of a number of factors including new drug launches, the phase 3 pipeline, recent quarterly performance and the expected patent expiry of several drugs. Overall, we believe that the company’s stock has upside potential, given its current level of $66 per share. This analysis provides an incisive snapshot of why we believe the company could unlock more value.
Have more questions about Bristol-Myers Squibb? See the links below.
- What’s Bristol-Myers Squibb’s Revenue And Earnings Breakdown?
- What’s Bristol-Myers Squibb’s Fundamental Value Based On Expected 2015 Results?
- How Has Bristol-Myers Squibb’s Revenue Composition Changed Over The Last 5 Years
- By What Percentage Can Bristol-Myers Squibb’s Revenue & EBITDA Grow In The Next 3 Years?
- How Much Revenues Can Bristol-Myers Squibb’s Phase 3 Pipeline Add By 2020?
- Bristol-Myers Squibb Did Well In 2015, And New Drugs Could Keep The Momentum Going
Relevant Articles
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
- Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Bristol-Myers Squibb
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)